TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06932263: A Phase IIb, Multicentre, Double-blind, Placebo-controlled Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adult Participants With Uncontrolled Asthma on Medium-to High Dose Inhaled Corticosteroi

Sponsor: AstraZeneca · Phase: PHASE2 · Area: IMMUNOLOGY · Target Enrollment: 540 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$414,000

Rescue Site Savings

+$276,000

Unlock Full NCT06932263 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06932263 Rescue Dossier →